GLP1R and ovarian carcinoma: Specifically, in the report by Dai et al., although the authors demonstrated reduced risks of endometrial cancer (hazard ratio [HR], 0.75 [95% CI, 0.57–0.99.57.99]; p = 0.05) and ovarian cancer (HR, 0.53 [95% CI, 0.29–0.96.29.96]; p = 0.04) by GLP-1 receptor agonist prescription, the wide confidence interval and borderline p value might diminish the confidence of their findings [141].